Tadashi Manabe, MD, PhD

Title(s)Postdoctoral Scholar, Medicine
SchoolSchool of Medicine
Address600 16th St
San Francisco CA 94158
ORCID ORCID Icon0000-0001-9891-5222 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Keio University Graduate School of Medicine, JapanPh.D.09/2020
    Keio University School of Medicine, JapanM.D.03/2012

    Collapse Research 
    Collapse Research Activities and Funding
    Uehara Memorial Foundation, Postdoctoral Fellowship Apr 1, 2021 - Mar 31, 2022
    Japan Society for the Promotion of Science, Research Fellowships for Young Scientists (DC2) 19J12401Apr 1, 2019 - Mar 31, 2021
    Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B) 17K16059Apr 1, 2017 - Mar 31, 2019

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Upregulation of fibroblast growth factor 9 in lung adenocarcinoma transdifferentiation to small cell lung cancer. Cancer Res. 2021 Jun 03. Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. PMID: 34083250.
      View in: PubMed   Mentions:    Fields:    
    2. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. Biochem Biophys Res Commun. 2021 01 01; 534:1-7. Kobayashi K, Terai H, Yasuda H, Hamamoto J, Hayashi Y, Takeuchi O, Mitsuishi Y, Masuzawa K, Manabe T, Ikemura S, Kawada I, Suzuki Y, Soejima K, Fukunaga K. PMID: 33302159.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    3. SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells. Mol Cancer Res. 2021 02; 19(2):317-328. Terai H, Hamamoto J, Emoto K, Masuda T, Manabe T, Kuronuma S, Kobayashi K, Masuzawa K, Ikemura S, Nakayama S, Kawada I, Suzuki Y, Takeuchi O, Suzuki Y, Ohtsuki S, Yasuda H, Soejima K, Fukunaga K. PMID: 33106373.
      View in: PubMed   Mentions: 1     Fields:    
    4. Adoptive transfer of zoledronate-expanded autologous V?9Vd2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. J Immunother Cancer. 2020 09; 8(2). Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J. PMID: 32948652.
      View in: PubMed   Mentions: 3     Fields:    
    5. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Mol Cancer Res. 2020 04; 18(4):549-559. Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada I, Hayashi Y, Fukui K, Horimoto K, Fukunaga K, Soejima K. PMID: 31941753.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    6. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. . 2019 09; 18(9):1593-1601. Oashi A, Yasuda H, Kobayashi K, Tani T, Hamamoto J, Masuzawa K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K. PMID: 31253648.
      View in: PubMed   Mentions:
    7. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 2019 05 14; 116(20):10025-10030. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. PMID: 31043566.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    8. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer. 2019 01; 127:146-152. Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K. PMID: 30642543.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    9. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther. 2018; 11:3335-3343. Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T. PMID: 29922072.
      View in: PubMed   Mentions: